Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ceva animal health pty ltd - iron as ferric hydroxide sucrose compound - parenteral liquid/solution/suspension - iron as ferric hydroxide sucrose compound mineral-iron-base active 20.0 mg/ml - nutrition & metabolism - horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare | pacer | pol - anaemia | iron deficiency | iron supplement | anaemia

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ceva animal health pty ltd - iron-sucrose complex - unknown - iron-sucrose complex mineral- iorn base active 0.0 - active constituent

Ireland - English - HPRA (Health Products Regulatory Authority)

vifor france - iron (iii) - solution for injection/infusion - 20 milligram(s)/millilitre - iron trivalent, oral preparations; saccharated iron oxide

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ausrichter pty ltd - iron-sucrose complex - parenteral liquid/solution/suspension - iron-sucrose complex mineral- iorn base active 20.0 mg - nutrition & metabolism - horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare | pacer | pol - iron deficiency | anaemia

Kenya - English - Pharmacy and Poisons Board

claris injectables limited off mombasa road, masai road, nairobi kenya - iron sucrose - solution for infusion - 20 mg/ml - antianemic preparations - iron preparations: iron

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

unimed sdn bhd - iron (iii)- hydroxide sucrose complex -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

averroes pharmaceuticals sdn. bhd. - iron (iii)- hydroxide sucrose complex -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

ain medicare sdn. bhd. - iron (iii)- hydroxide sucrose complex -

United States - English - NLM (National Library of Medicine)

fresenius medical care holdings, inc. - iron sucrose (unii: fz7nyf5n8l) (ferric cation - unii:91o4lml611) - ferric cation 20 mg in 1 ml - venofer is indicated for the treatment of iron deficiency anemia (ida) in patients with chronic kidney disease (ckd). - known hypersensitivity to venofer risk summary published studies on intravenous iron sucrose treatment after the first trimester of pregnancy have not shown adverse maternal or fetal outcomes (see data) . available reports of intravenous iron sucrose use in pregnant women during the first trimester are insufficient to assess the risk of major birth defects and miscarriage. there are risks to the mother and fetus associated with untreated ida in pregnancy as well as risks to the fetus associated with maternal severe hypersensitivity reactions (see clinical considerations) . animal reproduction studies of iron sucrose administered to rats and rabbits during the period of organogenesis at elemental iron doses equivalent to the maximum recommended human dose based on body surface area revealed no evidence of harm to the fetus (see data). the estimated background risk of major birth defects and

United States - English - NLM (National Library of Medicine)

american regent, inc. - iron sucrose (unii: fz7nyf5n8l) (ferric cation - unii:91o4lml611) - ferric cation 20 mg in 1 ml - venofer is indicated for the treatment of iron deficiency anemia (ida) in patients with chronic kidney disease (ckd). - known hypersensitivity to venofer. risk summary published studies on intravenous iron sucrose treatment after the first trimester of pregnancy have not shown adverse maternal or fetal outcomes (see data) . available reports of intravenous iron sucrose use in pregnant women during the first trimester are insufficient to assess the risk of major birth defects and miscarriage. there are risks to the mother and fetus associated with untreated ida in pregnancy as well as risks to the fetus associated with maternal severe hypersensitivity reactions (see clinical considerations) . animal reproduction studies of iron sucrose administered to rats and rabbits during the period of organogenesis at elemental iron doses equivalent to the maximum recommended human dose based on body surface area revealed no evidence of harm to the fetus (see data). the estimated background risk of major birth defects and